These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23768633)

  • 1. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience?
    Baum M
    Eur Urol; 2013 Oct; 64(4):540-1. PubMed ID: 23768633
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply from authors re: Michael Baum. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience? Eur Urol 2013;64:540-1: screening for prostate cancer: we have learned and are still learning.
    Roobol MJ; Kranse R; Bangma CH; Otto SJ; van der Kwast TH; Bokhorst LP; de Koning HJ; Schröder FH
    Eur Urol; 2013 Oct; 64(4):541-3. PubMed ID: 23816273
    [No Abstract]   [Full Text] [Related]  

  • 3. Strengthening evidence for active surveillance for prostate cancer.
    Klotz L
    Eur Urol; 2013 Jan; 63(1):108-10. PubMed ID: 23122665
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate-specific antigen-based screening for prostate cancer: the irony of it all.
    Carter HB
    Eur Urol; 2013 Nov; 64(5):710-1; discussion 711-2. PubMed ID: 23773555
    [No Abstract]   [Full Text] [Related]  

  • 5. Healing or harming: the prostate cancer dichotomy.
    Zarrabi A; Mark S
    N Z Med J; 2020 Oct; 133(1523):12-15. PubMed ID: 33032299
    [No Abstract]   [Full Text] [Related]  

  • 6. Managing localized prostate cancer in the era of prostate-specific antigen screening.
    Brooks JD
    Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer options expand beyond the PSA.
    Clin Resour Manag; 2002 May; 3(5):65-8. PubMed ID: 12048767
    [No Abstract]   [Full Text] [Related]  

  • 8. Doing it right: how, not whether, to perform prostate-specific antigen screening.
    Martin NE
    Eur Urol; 2015 Sep; 68(3):361-2. PubMed ID: 25794459
    [No Abstract]   [Full Text] [Related]  

  • 9. The dilemmas of prostate cancer screening.
    Del Mar CB
    Med J Aust; 2013 Nov; 199(9):584. PubMed ID: 24182218
    [No Abstract]   [Full Text] [Related]  

  • 10. The dilemmas of prostate cancer screening.
    Hugosson J; Carlsson SV
    Med J Aust; 2013 Nov; 199(9):583-4. PubMed ID: 24182217
    [No Abstract]   [Full Text] [Related]  

  • 11. The dilemmas of prostate cancer screening.
    Lawrentschuk N; Murphy DG; Costello AJ
    Med J Aust; 2013 Nov; 199(9):583. PubMed ID: 24182216
    [No Abstract]   [Full Text] [Related]  

  • 12. The dilemmas of prostate cancer screening.
    Haines IE
    Med J Aust; 2013 Nov; 199(9):582-3. PubMed ID: 24182215
    [No Abstract]   [Full Text] [Related]  

  • 13. The dilemmas of prostate cancer screening.
    McKenzie PR; Delahunt B; Kench JG
    Med J Aust; 2013 Nov; 199(9):582. PubMed ID: 24182214
    [No Abstract]   [Full Text] [Related]  

  • 14. The dilemmas of prostate cancer screening.
    Miklos GG
    Med J Aust; 2013 Nov; 199(9):582. PubMed ID: 24182213
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate-specific antigen screening for prostate cancer in males older than 75 years.
    Luján M; Páez Á
    Med Clin (Barc); 2019 Mar; 152(6):237-240. PubMed ID: 30220470
    [No Abstract]   [Full Text] [Related]  

  • 16. Valentine's Day PSA.
    Dasgupta P
    BJU Int; 2014 Feb; 113(2):177. PubMed ID: 24712694
    [No Abstract]   [Full Text] [Related]  

  • 17. 5-Alpha reductase inhibitors and PSA screening for prostate cancer.
    McKenzie PR; Delahunt B; Kench JG; Sikaris KA
    Pathology; 2014 Jan; 46(1):91-2. PubMed ID: 24300730
    [No Abstract]   [Full Text] [Related]  

  • 18. 5-Alpha reductase inhibitors and PSA screening for prostate cancer.
    Zardawi IM
    Pathology; 2014 Jan; 46(1):91. PubMed ID: 24300722
    [No Abstract]   [Full Text] [Related]  

  • 19. Unorganized prostate-specific antigen-based screening for prostate cancer: more harm than benefit. When will we finally start to implement guidelines and risk assessment tools in clinical practice?
    Roobol MJ
    Eur Urol; 2015 Sep; 68(3):363-4. PubMed ID: 25769985
    [No Abstract]   [Full Text] [Related]  

  • 20. Can the results of the European Randomized Study of Screening for Prostate Cancer be decontaminated?
    Metcalfe C
    Eur Urol; 2014 Feb; 65(2):337-8; discussion 338-9. PubMed ID: 24050792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.